Breakthrough Therapy Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
GLTO | A | Galecto, Inc. | -6.29 | |
PROK | B | ProKidney Corp. | 2.17 | |
REGN | B | Regeneron Pharmaceuticals, Inc. | -2.63 | |
TSVT | C | 2seventy bio, Inc. | -1.66 | |
VRTX | D | Vertex Pharmaceuticals Incorporated | -4.93 | |
PPBT | D | Purple Biotech Ltd. | -2.38 | |
HUMA | D | Humacyte, Inc. | 0.31 | |
GMAB | D | Genmab A/S | -0.71 | |
CMPS | D | COMPASS Pathways Plc | -6.97 | |
ACHL | D | Achilles Therapeutics plc | -1.64 |
Related Industries: Biotechnology Drug Manufacturers-General Long-Term Care Facilities Medical Care Facilities
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
IBB | D | iShares Nasdaq Biotechnology Index Fund | 15.97 | |
IBBQ | D | Invesco Nasdaq Biotechnology ETF | 15.19 | |
PSIL | D | AdvisorShares Psychedelics ETF | 12.26 | |
BBH | C | Market Vectors Biotech ETF | 12.02 | |
KONG | B | Formidable Fortress ETF | 11.58 |
Compare ETFs
- Breakthrough Therapy
Breakthrough therapy is a United States Food and Drug Administration designation that expedites drug development that was created by Congress under Section 902 of the 9 July 2012 Food and Drug Administration Safety and Innovation Act. The FDA's "breakthrough therapy" designation is not intended to imply that a drug is actually a "breakthrough" or that there is high-quality evidence of treatment efficacy for a particular condition; rather, it allows the FDA to grant priority review to drug candidates if preliminary clinical trials indicate that the therapy may offer substantial treatment advantages over existing options for patients with serious or life-threatening diseases. The FDA has other mechanisms for expediting the review and approval process for promising drugs, including fast track designation, accelerated approval, and priority review.
Mike's Notes
- GOOG: One of my fa...
- WFC: While lookin...
- SPY: This is more...
- IWM: How things h...
- TSLA: Tesla had it...
From the Blog
Featured Articles